echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > LENZ Therapeutics and Keixing Pharmaceutical reach an exclusive license agreement in Greater China

    LENZ Therapeutics and Keixing Pharmaceutical reach an exclusive license agreement in Greater China

    • Last Update: 2022-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 14, LENZ Therapeutics announced that it has signed an exclusive agreement with Keixing Pharma to develop and commercialize LNZ100 (acetylcridine) and LNZ101 (acetylcridine + brimonidine) for the treatment of presbyopia in Greater China.


    Under the terms of the agreement, LENZ will receive an upfront payment of $15 million and may receive additional payments of up to $95 million, subject to development, approval and commercialization milestones and franchises based on future net sales usage fee


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.